Compare PNTG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | TSHA |
|---|---|---|
| Founded | 2019 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2019 | 2020 |
| Metric | PNTG | TSHA |
|---|---|---|
| Price | $41.03 | $4.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $46.83 | $13.00 |
| AVG Volume (30 Days) | 274.5K | ★ 3.4M |
| Earning Date | 11-17-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | 5.56 |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $947,705,000.00 | $9,773,000.00 |
| Revenue This Year | $24.90 | N/A |
| Revenue Next Year | $7.79 | $1,023.00 |
| P/E Ratio | $83.29 | ★ N/A |
| Revenue Growth | ★ 36.31 | 17.28 |
| 52 Week Low | $22.26 | $3.46 |
| 52 Week High | $43.41 | $7.30 |
| Indicator | PNTG | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 43.93 |
| Support Level | $37.81 | $3.46 |
| Resistance Level | $41.07 | $4.72 |
| Average True Range (ATR) | 1.27 | 0.25 |
| MACD | -0.16 | 0.06 |
| Stochastic Oscillator | 14.20 | 61.86 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments; home health and hospice services and senior living services. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.